Skip to main content
Figure 2 | Lipids in Health and Disease

Figure 2

From: Oral bioavailability of the ether lipid plasmalogen precursor, PPI-1011, in the rabbit: a new therapeutic strategy for Alzheimer's disease

Figure 2

Incorporation of [13C 22 ]PPI-1038 into plasma DHA-containing ethanolamine plasmalogens (PlsEtn) 6, 24 and 48 hours after an oral dose of 100 mg/kg in a gelatin capsule. N = 1 rabbit. Figure A, Labeling of PlsEtn 16:0/22:6 (D3, [13C3]DHA; G3, [13C3]glycerol; P16, [13C16]palmitic acid); Figure B, [13C3]DHA labeling of PlsEtn 18:0/22:6 and PlsEtn 18:1/22:6.

Back to article page
\